Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

1.5K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.5K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.8K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.7K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.7K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Host immunosuppression and antifungal pressure cooperatively shape fungal adaptation and pulmonary microenvironment in cryptococcosis.

Microbial pathogenesis·2026
Same author

Antifungal resistance: from classical mechanisms to the expanding role of acetyltransferases.

Journal of biomedical science·2026
Same author

Platysma Easy Clip: a less invasive technique for cervical rejuvenation with 100 clinical cases.

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery·2026
Same author

P2X7 receptor blockade during Cryptococcus neoformans infection promotes a Th2-associated immune profile and enhances fungal dissemination to the brain.

International immunopharmacology·2026
Same author

Anticryptococcal Evaluation of the Allylimine 3H2: Modulation of Virulence Traits and Synergistic Action with Amphotericin B.

ACS omega·2026
Same author

Dismantling darkness: interdisciplinary perspectives on melanin degradation.

World journal of microbiology & biotechnology·2026

Related Experiment Video

Updated: Mar 3, 2026

Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks
09:18

Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks

Published on: December 2, 2022

1.4K

Atorvastatin as a promising anticryptococcal agent.

Noelly de Queiroz Ribeiro1, Marliete Carvalho Costa1, Thaís Furtado Ferreira Magalhães1

  • 1Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Minas Gerais, Brazil.

International Journal of Antimicrobial Agents
|April 29, 2017
PubMed
Summary

Atorvastatin combined with fluconazole shows promise in treating Cryptococcus gattii infections. This drug combination improved survival and reduced fungal burden in a mouse model, offering a new therapeutic strategy.

Keywords:
AtorvastatinCryptococcus gattiiDrug repositioning

More Related Videos

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

8.4K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.5K

Related Experiment Videos

Last Updated: Mar 3, 2026

Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks
09:18

Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks

Published on: December 2, 2022

1.4K
Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

8.4K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.5K

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Cryptococcosis, caused by Cryptococcus gattii, presents a significant global health challenge with high mortality due to limited treatment options and rising drug resistance.
  • Drug repositioning offers a viable strategy to identify novel therapeutic approaches for cryptococcosis.
  • Atorvastatin (ATO), a cholesterol-lowering drug, is explored as a potential adjuvant therapy.

Purpose of the Study:

  • To evaluate Atorvastatin (ATO) as an adjuvant therapy for Cryptococcus gattii infections.
  • To investigate the combined efficacy of ATO and fluconazole (FLC) against C. gattii.
  • To assess the impact of ATO+FLC on host immune response and fungal characteristics.

Main Methods:

  • In vitro assessment of ATO's effects on C. gattii cell membrane ergosterol and capsule properties.
  • Evaluation of ATO's impact on macrophage production of reactive oxygen species.
  • In vivo study using a murine model of cryptococcosis treated with ATO+FLC.

Main Results:

  • ATO+FLC reduced ergosterol content and altered the C. gattii capsule.
  • The combination enhanced macrophage reactive oxygen species production.
  • ATO+FLC treatment led to increased survival rates, improved clinical status, and reduced fungal load in the lungs and brain of infected mice.

Conclusions:

  • Atorvastatin shows potential as an effective adjuvant in combination with fluconazole for treating cryptococcosis.
  • The ATO+FLC combination demonstrates significant therapeutic benefits in a preclinical animal model.
  • This study provides the first in vivo evidence supporting ATO+FLC as a treatment for cryptococcosis.